Virology and Immunology of HIV/AIDS

Understanding the Virology and Immunology of HIV/AIDS

Human Immunodeficiency Virus (HIV) remains one of the most studied pathogens in modern virology. This course synthesizes key concepts from a typical quiz, turning multiple‑choice items into a comprehensive, SEO‑friendly learning module. By the end of this lesson, you will understand how HIV enters cells, replicates, integrates, evades the immune system, and how current therapies target its life cycle.

1. HIV Entry: The Role of gp120

The first step in infection is viral attachment and fusion. The viral envelope protein gp120 binds to the CD4 receptor on helper T cells, then engages a chemokine co‑receptor (CCR5 or CXCR4). This dual‑receptor interaction triggers a conformational change in the transmembrane protein gp41, allowing the viral membrane to fuse with the host cell membrane.

• Key point: gp120 is the primary determinant of tropism and a major target for neutralizing antibodies.
• Why gp120 matters for vaccine design: its high variability makes it difficult to generate broadly protective responses.

2. Reverse Transcription: Converting RNA to DNA

After fusion, HIV releases its RNA genome into the cytoplasm. The enzyme reverse transcriptase (RT) synthesizes a complementary DNA (cDNA) strand, then degrades the RNA template and creates a double‑stranded DNA (dsDNA) copy. This step is error‑prone, contributing to HIV’s rapid mutation rate.

• RT has both polymerase and RNase H activities.
• Inhibitors such as nucleoside reverse transcriptase inhibitors (NRTIs) and non‑nucleoside reverse transcriptase inhibitors (NNRTIs) block this step.

3. Primary Cellular Targets of HIV

HIV preferentially infects cells that express CD4 and the appropriate co‑receptor. The main targets are:

• CD4⁺ T lymphocytes – central to adaptive immunity.
• Macrophages – serve as viral reservoirs in tissues.
• Dendritic cells – capture virus and present it to T cells, facilitating spread.

Neutrophils, despite being abundant, lack CD4 and are not primary targets of HIV infection.

4. Integration: The Action of Integrase

Once reverse transcription yields dsDNA, the viral enzyme integrase inserts this proviral DNA into the host genome. Integration is a critical, irreversible step that establishes a permanent viral reservoir.

• Integrase inhibitors (e.g., raltegravir) block the strand‑transfer reaction, preventing provirus formation.
• Integrated proviruses can remain transcriptionally silent, forming the basis of HIV latency.

5. Latency: Why HIV Persists for Years

Latent infection occurs when the provirus integrates into host DNA but does not actively produce viral proteins. This silent state allows HIV to evade immune detection and persist despite antiretroviral therapy.

• Key mechanism: The provirus can be transcriptionally repressed by host chromatin modifications.
• Latent reservoirs are primarily found in resting CD4⁺ T cells and tissue macrophages.

6. CD8⁺ T Cell Dynamics

Early in infection, cytotoxic CD8⁺ T lymphocytes (CTLs) recognize and kill infected cells, limiting viral replication. Over time, however, the virus accumulates mutations that alter epitopes, allowing escape from CTL recognition.

• Viral escape is driven by the high mutation rate of reverse transcription.
• Chronic activation can also lead to T‑cell exhaustion, reducing CTL efficacy.

7. Antiretroviral Therapy (ART): Combination Strategy

Effective ART regimens combine drugs that target multiple steps of the HIV life cycle:

• Reverse transcriptase inhibitors (NRTIs/NNRTIs)
• Protease inhibitors – block cleavage of viral polyproteins.
• Integrase inhibitors – prevent proviral integration.

By attacking several enzymes simultaneously, ART suppresses viral load, restores immune function, and reduces the chance of resistance.

8. Challenges with gp120‑Based Vaccines

Vaccines that focus solely on gp120 have struggled because:

• gp120 exhibits high variability across HIV subtypes, limiting cross‑protective antibody responses.
• The protein’s extensive glycosylation shields conserved epitopes from immune recognition.
• Broadly neutralizing antibodies (bNAbs) often target conformational epitopes that are difficult to mimic with simple gp120 immunogens.

Current vaccine research therefore explores mosaic antigens, conserved region immunogens, and vector‑based strategies to overcome gp120 variability.

9. Summary of Core Concepts

Understanding HIV/AIDS requires integrating virology and immunology:

• Entry: gp120 binds CD4 and a chemokine co‑receptor.
• Reverse transcription: RT synthesizes DNA from RNA.
• Integration: Integrase inserts proviral DNA into the host genome.
• Primary targets: CD4⁺ T cells, macrophages, dendritic cells (not neutrophils).
• Latency: Integrated provirus can remain silent for years.
• Immune evasion: Viral mutants escape CD8⁺ T‑cell recognition.
• Therapy: ART combines RT, protease, and integrase inhibitors.
• Vaccine hurdles: gp120 variability limits broad protection.

10. Frequently Asked Questions (FAQ)

Q: Can ART eradicate HIV?

A: No. ART suppresses replication but does not eliminate latent proviruses; lifelong therapy is currently required.

Q: Why are neutrophils not infected?

A: They lack CD4 receptors and the necessary co‑receptors, making them resistant to HIV entry.

Q: What is the significance of broadly neutralizing antibodies?

A: bNAbs target conserved regions of gp120/gp41 and are a promising avenue for vaccine design.